DUSA - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

Profile:  


DUSA Pharmaceuticals Inc.
25 Upton Drive
Wilmington, MA 01887
United States - Map
Phone: 978-657-7500
Fax: 416-363-6602
Web Site: http://www.dusapharma.com

DETAILS  
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 83


BUSINESS SUMMARY:
 
DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of actinic keratoses of the face or scalp. Kerastick is a disposable applicator used for the rapid preparation and uniform application of Levulan topical solution in standardized doses. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing Levulan PDT, a Phase II clinical trial product to treat photodamaged skin, moderate to severe acne vulgaris, Barrett?s esophagus dysplasia using DUSA endoscopic light delivery system, and oral cavity dysplasia. In addition, the company is developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, and Psoriatec for the treatment of acne vulgaris and acne rosacea, as well as psoriasis; ClindaReach; Meted Shampoo; and Psoriacap. The company was founded in 1991 and is based in Wilmington, Massachusetts.



Business Overview:

BRIEF: For the fiscal year ended 31 December 2006, Dusa Pharmaceuticals, Inc.'s revenues totaled $25.6M, up from $11.3M. Net loss totaled $31.3M, up from $15M. Revenues reflect higher sales from total PDT Drugs & Device Products and an increase in Kerastick sales. Higher loss reflects the presence of $15.7M impairment of intangible assets charges, the presence of $1.6M in-process R&D expenses and higher marketing & sales expenses. http://www.dusapharma.com

[setravis]

CHICAGO, May 17 (Reuters) - Dusa Pharmaceuticals Inc. (DUSA,Trade) on Thursday said it received orphan drug designation from the U.S. Food and Drug Administration for Levulan, its treatment for esophageal dysplasia

The disease occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. The incidence of esophageal cancer is one of the most rapidly growing in the United States, with more than 11,000 new diagnoses each year, the company said.

Patients diagnosed with high-grade dysplasia are at high risk for developing esophageal cancer and currently have limited treatment options, Dusa said.

[setravis]

Bottom fishing to the max...Extremely risky.
Throwing on watch list for now....I don't want to get caught on the downside.
Looking for the pullback !
Above the 50 and 200-day MA...Via Gap Up

Float (mil) 17.80...Shares Outstanding (mil) 19.48

52wk Range: 2.75 - 6.79
Volume: 23,093,165
Avg Vol (3m): 49,216.1

Technicals
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
51.60%above 13-day MA
37.91%above 50-day MA
RS Rating: 80 

Fundamentals
Key Data:
Market Cap (M): $61.95 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Hold

[setravis]

Gerber Scientific, DUSA Pharmaceuticals: Biggest Price Gainers (GRB, DUSA)
May 17, 2007 1:47 p.m.

Gerber Scientific Inc. topped the list of Biggest Percentage Price Gainers on the New York Stock Exchange at midday on Thursday. +31.39%

DUSA Pharmaceuticals Inc. the list of Biggest Percentage Price Gainers on the Nasdaq Stock Market.  +71.90%

[setravis]

Getting profitable, downtrend reversal...
After a long long decline DUSA´s share price has found a bottom.
Without debt the company is not going out of business soon,and is now on the verge of getting profitable.
With a shareprice around $2.14, and a market cap of only 43M right now, it is completely below the radars.
With positive earnings ahead this may change, buying here should be rewarded. For now, it is trading with low volume, Limit Orders are mandatory here.


52wk Range: 0.88 - 2.25
Volume: 643,450
Avg Vol (3m): 61,364.5

Technicals
Record Price High
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
20.34%above 13-day MA
30.17%above 50-day MA
RS Rating: 90

Fundamentals
Earnings Expected on May 11

Key Data:
Market Cap (M): $43.88 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2010
Last Analyst Rating: Mkt Outperform


Below are the 6 month and 1 year charts...
Breakout of a Symmetrical Triangle into an Ascending Triangle..BreakOut...

[setravis]

Getting profitable, downtrend reversal...
After a long, long decline DUSA's share price has found the way North.

Day's Range: 3.64 - 4.35
52wk Range: 1.51 - 4.35
Volume: 2,851,578
Avg Vol (3m): 42,621
Market Cap: 98.85M
P/E (ttm): 680.00
EPS (ttm): 0.01
Div & Yield: N/A (N/A)

Technicals
Record Price High
Close Above the 13-day EMA
Record Price Break Out
Gap Up
Percentage Gainer

Last Price Quote is:
33.07%above 13-day EMA
40.76%above 50-day EMA
RS Rating: 94